Jubilant Pharmova

895.90
+7.20
(0.81%)
Market Cap
14,270.00 Cr
EPS
4.87
PE Ratio
42.14
Dividend Yield
0.56 %
Industry
Healthcare
52 Week High
1,309.90
52 Week Low
562.70
PB Ratio
2.39
Debt to Equity
0.68
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+100.00 %
+100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,734.70
#1 4,16,212.64
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.74
5,775.45
1,53,320.05
75.20
8,184.00
0.89
1,600
#1 64.53
50.68
1,442.20
1,16,474.23
24.00
26,520.70
14.17
4,155
47.38
42.46
3,227.95
1,09,248.50
58.64
10,785.70
11.59
1,656
13.54
59.06
2,424.75
1,00,039.98
49.78
10,615.60
19.57
1,942
-16.38
57.16
1,144.20
95,478.38
#1 18.06
28,905.40
12.36
5,578
1.69
43.23
2,027.95
92,584.22
32.14
20,141.50
#1 19.94
1,936
38.82
48.77
886.40
89,192.58
19.77
19,831.50
13.82
3,831
29.92
41.50
1,160.50
67,402.03
19.21
29,559.20
17.55
3,169
-10.04
52.98
30,720.55
65,279.02
48.70
6,097.20
10.80
1,201
16.01
56.63
Growth Rate
Revenue Growth
7.15 %
Net Income Growth
-212.02 %
Cash Flow Change
47.01 %
ROE
-211.67 %
ROCE
99.13 %
EBITDA Margin (Avg.)
11.09 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
Investments
0
85
103
124
115
69
241
239
256
42
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
Share Capital
16
16
16
16
16
16
16
16
16
16

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 0.00
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.00

Corporate Action

Announcements

Amended And Restated Deed Of Private Trust Dated March 25 20256 days ago
Closure of Trading Window7 days ago
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With PieMar 20, 2025
Announcement Under Regulation 30 - USFDA Report For Jubilant Cadista Pharmaceuticals Inc. USAMar 12, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Audio Recording Of Investors / Analysts MeetingFeb 24, 2025
Presentation For Investor And Analyst MeetFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Integrated Filing (Financial)Jan 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Unaudited Results For The Quarter Ended December 31 2024Jan 31, 2025
Board Meeting Outcome for Outcome Of Board MeetingJan 31, 2025
Announcement Under Regulation 30 - Jubilant Biosys Innovative Research Services Pte Limited Singapore (JBIRSPL) A Subsidiary Of Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has ExeJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
The Company Has Informed The Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 214 Cr.Jan 24, 2025
Board Meeting Intimation for Intimation For Board Meeting Scheduled On January 31 2025 To Consider The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Jan 23, 2025
USFDA Inspection In Companys Subsidiary Jubilant Cadista Pharmaceuticals Inc.Jan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingDec 10, 2024
Deferment Of Investor/ Analysts MeetingNov 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 25, 2024
Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Announcement - Voluntary Prepayment Of USD 25 Million Term Loan, Equivalent To Rs. 210 CrOct 24, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 19, 2024
Board Meeting Intimation for Intimation Of Board MeetingOct 17, 2024
Deletion Of Tax Deman Raised On Jubilant Generics Ltd - Step Down SusbsidiaryOct 10, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 09, 2024
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 04, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementOct 01, 2024
Announcement Under Regulation 30Oct 01, 2024
Closure of Trading WindowSep 30, 2024
Communication From USFDASep 28, 2024
Communication From USFDA.Sep 26, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Sep 20, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2024
Announcement Under Regulation 30 - Communication From USFDASep 10, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 30, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 24, 2024
Postal Ballot Results Alongwith Scrutinizers ReportAug 23, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 16, 2024
Jubilant Biosys Limited, A Wholly Owned Subsidiary Of The Company, Has Signed And Issued A 'Put Option Offer' To Pierre Fabre Laboratories, Which Sets Forth An Offer To Acquire 80% Equity Capital (Approx. Euro 4.4 Million Over A Period Of 2 Years) In A New Company To Be Incorporated In France, Which New Company Shall Acquire Pierre Fabre'S R&D Centre (Including R&D Site And R&D Activities) At Saint Julien, France.Aug 16, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2024
Reg. 34 (1) Annual Report.Aug 09, 2024
Notice Of 46Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2023-24Aug 08, 2024
Business Responsibility and Sustainability Reporting (BRSR)Aug 08, 2024

Technical Indicators

RSI(14)
Neutral
47.09
ATR(14)
Less Volatile
38.98
STOCH(9,6)
Neutral
51.19
STOCH RSI(14)
Neutral
73.03
MACD(12,26)
Bullish
3.39
ADX(14)
Weak Trend
14.27
UO(9)
Bearish
45.56
ROC(12)
Uptrend And Accelerating
0.57
WillR(14)
Neutral
-38.98

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Chairperson NameShyam S Bhartia